Institute of Pathology, Molecular Hepatopathology, University Hospital Heidelberg, Heidelberg, Germany.
Int J Cancer. 2012 Nov 1;131(9):2016-26. doi: 10.1002/ijc.27473. Epub 2012 Mar 27.
Stability of many tumor-relevant proteins is partly mediated by E3 ligases, which determine substrate specificity within the ubiquitin system. Recent data demonstrated that increased nuclear expression of the E3 ligase seven in absentia homologue (SIAH)-1 in human hepatocarcinogenesis supports tumor cell proliferation and migration. To define whether closely related SIAH-2 synergizes with protumorigenic SIAH-1, we systematically analyzed expression, localization and functional relevance of SIAH-2 in human hepatocellular carcinoma (HCC). Nuclear accumulation of SIAH-2 is detectable in more than 60% of all HCCs and correlates with tumor progression, cell proliferation and distant metastasis. An inverse correlation between nuclear SIAH-1 and SIAH-2 was detected, suggesting independent mechanisms for nuclear enrichment. Inhibition of nuclear SIAH-2 by RNAi in HCC cell lines reduced proliferation as well as lateral tumor cell motility and transmigration; however, combined knock down of both SIAH-1 and SIAH-2 did not further amplify biological effects compared to single gene inhibition. Reduction of SIAH-2 expression sensitizes HCC cells to the treatment with different cytostatic drugs, demonstrating that SIAH-2-targeting approaches may increase the response of HCC cells to conventional chemotherapy. Together, these data show that SIAH-2--as described for SIAH-1--accumulates in nuclei of HCC cells where it supports tumor growth and tumor cell dissemination. Because the nuclear pattern of SIAH-2 differs in HCC tissues from the SIAH-1 pattern and because the inactivation of SIAH-2 is not compensated by SIAH-1, the specific inhibition of SIAH-2 (especially in combination with other drugs) represents a promising therapeutic strategy for HCC.
许多肿瘤相关蛋白的稳定性部分受 E3 连接酶调节,E3 连接酶决定泛素系统中的底物特异性。最近的数据表明,在人类肝癌发生过程中,E3 连接酶 absentia 同源物(SIAH)-1 的核表达增加支持肿瘤细胞增殖和迁移。为了确定密切相关的 SIAH-2 是否与促肿瘤发生的 SIAH-1 协同作用,我们系统地分析了 SIAH-2 在人肝细胞癌(HCC)中的表达、定位和功能相关性。超过 60%的所有 HCC 中都可检测到 SIAH-2 的核积累,并且与肿瘤进展、细胞增殖和远处转移相关。检测到核 SIAH-1 和 SIAH-2 之间的负相关,表明核富集的独立机制。在 HCC 细胞系中通过 RNAi 抑制核 SIAH-2 减少了增殖以及侧向肿瘤细胞迁移和迁移;然而,与单基因抑制相比,同时敲低 SIAH-1 和 SIAH-2 并没有进一步放大生物学效应。降低 SIAH-2 的表达使 HCC 细胞对不同细胞毒性药物的治疗更加敏感,表明针对 SIAH-2 的方法可能增加 HCC 细胞对常规化疗的反应。总之,这些数据表明 SIAH-2-正如 SIAH-1 所描述的那样-在 HCC 细胞的核中积累,在那里它支持肿瘤生长和肿瘤细胞扩散。由于 SIAH-2 在 HCC 组织中的核模式与 SIAH-1 模式不同,并且 SIAH-2 的失活不能被 SIAH-1 代偿,因此特异性抑制 SIAH-2(尤其是与其他药物联合使用)代表了 HCC 的一种有前途的治疗策略。